Outsourcing facilities are only allowed to compound drugs with five bulk substances — diphenylcyclopropenone, glycolic acid, quinacrine hydrochloride, squaric acid dibutyl ester and trichloroacetic acid — for specific uses, such as topical or oral use.
The FDA has evaluated and blocked 20 other solutions from joining the list, according to documents.
